

# The 10th International Advanced Course on Vaccinology in Asia Pacific Regions

IVI, Seoul, May 10-15, 2010

## DRAFT AGENDA

### DAY 1: Monday, May 10, 2010

930 1000 Welcome address and IVI introduction J Clemens

#### **EPIDEMIOLOGY**

##### **Chairperson:**

1000 1100 Vaccines and diseases control, elimination, and eradication F Andre TAB 1

1100 1115 Coffee break

1115 1200 Risks rates and measures of transmissibility R Ochiai TAB 2

1200 1300 Lunch

1300 1330 Study designs for vaccine evaluation S Grahek TAB 3

1330 1400 Surveillance: definition, goals and methodology M Favorov TAB 4

1400 1430 Ethical principles and review: the role of the IRB in the ethical review of vaccine clinical trials H Kwon TAB 5

1430 1445 Coffee break

#### **IMMUNOBIOLOGY**

##### **Chairperson:**

1445 1530 Vaccine concepts: immunological basis C Czerkinsky TAB 6

1530 1615 Basic principles of immune responses: innate versus adaptive immunity H Kiyono TAB 7

1615 1645 Immunological basis of mucosal vaccines M Kweon TAB 8

1730 1930 **Welcome reception** **at the IVI Lobby**

### DAY 2: Tuesday, May 11, 2010

#### **MOVING FROM DISCOVERY TO LICENSED PRODUCT**

##### **Chairperson:**

900 1000 Vaccine and Antigen delivery systems M Liu TAB 9

1000 1015 Coffee break

1015 1045 Role of regulatory agencies G Smith TAB 10

1045 1130 Development and GMP production of vaccines R Carbis TAB 11

1130 1230 Lunch

##### **Chairperson:**

1230 1400 New vaccine evaluation: phase I - III J Clemens TAB 12

1400 1415 Coffee break

1415 1510 Phase I-III pneumococcal conjugate clinical trials: case study P Kilgore TAB 13

1600 **Seoul sightseeing**

**DAY 3: Wednesday, May 12, 2010**

**MOVING FROM LICENSING TO INTRODUCTION**

**Chairperson:**

900	9040	Phase 3B studies: demonstration projects	J Clemens	TAB 14
940	1020	Population-based post-licensure surveillance	P Zuber	TAB 15
1020	1035	Coffee break		
1035	1105	Herd immunity conferred by vaccines	J Clemens	TAB 16
1105	1150	Special issues related to control of pandemic influenza vaccine	F Ahmed	TAB 17
1150	1300	Lunch		

**MOVING FROM LICENSING TO INTRODUCTION (2)**

**Chairperson:**

1300	1400	The changing regulatory environment: the rotavirus vaccine case	I Gust	TAB 18
1400	1430	Asian regulatory perspective and trends	S Cook	TAB 19
1430	1445	Coffee break		
1445	1530	AEFIs and risk communication	F Andre	TAB 20
1530	1700	Case study on TBA		

**DAY 4: Thursday, May 13, 2010**

**PRODUCT DEVELOPMENT PARTNERSHIPS**

**Chairperson:**

900	940	Introductory lecture on PDP historical background and basic concepts	R Mahoney	TAB 21
940	1100	PDPs: models of accelerating the development and introduction of developing country vaccines with local producers/big pharma: Cholera Vaccines (40 mins) HIV Vaccines (40 mins)	R Cabris S Kochhar	TAB 22 TAB 23
1100	1115	Coffee break		
1115	1315	PDPs: models of accelerating the development and introduction of developing country vaccines with local producers/big pharma: HPV Vaccines (40 mins) Dengue Vaccines (40 mins) Typhoid Vaccines (40 mins)	C Llave B Letson S Shin	TAB 24 TAB 25 TAB 26
1315	1410	Lunch		
1410	1510	Technology transfer Technology transfer: an IVI perspective Development and technology transfer of cost-effective conjugate vaccine against <i>Haemophilus influenzae</i> type b	S Kothari M Beurret	TAB 27 TAB 28
1510	1525	Coffee break		
1525	1625	IVI laboratory tour		
1625		Group Photo		

**DAY 5: Friday, May 14, 2010**

**MOVING FROM LICENSURE TO USE**

**Chairperson:**

900	930	Evidence-based decision-making process for vaccine introduction	F Ahmed	TAB 29
930	1000	Health economics: principles and methods	B Maskery	TAB 30
1000	1015	Coffee break		

**Introduction of new vaccines with emphasis in the Asia region:**

1015	1045	Introduction of Hepatitis B vaccines in Asia	M Favorov	TAB 31
1045	1115	Hib vaccine introduction in the region	K Edmund	TAB 32
1115	1145	Rotavirus vaccine introduction	T Nelson	TAB 33
1145	1300	Lunch		

**Programmatic Considerations:**

1300	1330	Financing mechanisms for vaccines: an overview	A Levin	TAB 34
1330	1400	Financing mechanisms for GAVI eligible countries	A Levin	TAB 35
1400	1430	Development of investment case for cholera vaccines	B Maskery	TAB 36
1430	1530	Round table discussion	Chaired by TBA, F Andre, A Levin, F Ahmed, T Nelson, B Maskery	

1530 1545 Coffee break

**Chairperson:**

1545	1630	Sharing experience: injection safety assessment and adverse event monitoring Discussion on participants' practical experiences	A Amarasinghe	TAB 37
------	------	---	---------------	--------

**Sharing experience: vaccine introduction in GAVI Programs  
- cold chain, logistics**

1630	1700	WHO perspective	S Kone	TAB 38
1700	1730	Industry perspective	D Kohl	TAB 39
1730	1820	Discussion on participants' practical experiences		

**DAY 6: Saturday, May 15, 2010**

**SPECIAL LECTURES**

**Chairperson: J Clemens**

900	1030	Keynote closing speech - the future of vaccines and vaccination with special emphasis on avian flu and other pandemics	I Gust	TAB 40
1030	1100	Coffee break		
1100	1200	Closing ceremony	J Clemens	
1200	1400	Lunch		